New insights into acquired endocrine resistance of breast cancer
作者机构:Department of Breast Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonTX 77030USA.
出 版 物:《Cancer Drug Resistance》 (癌症耐药(英文))
年 卷 期:2019年第2卷第2期
页 面:198-209页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:This work was supported by the NIH/NCI(P30-CA016672)(Peter Pisters) Susan G.Komen for the Cure Foundation(SAC100009)to Jordan VC Cancer Prevention Research Institute of Texas(CPRIT)for the STARs and STARs plus Awards to Jordan VC the George and Barbara Bush Foundation for Innovative Cancer Research to Jordan VC the benefactors of the Dallas/Fort Worth Living Legend Chair of Cancer Research to Jordan VC
主 题:Estrogen receptorα endocrine resistance endoplasmic reticulum stress estrogen-induced apoptosis breast cancer
摘 要:The translational research strategy of targeting estrogen receptorα(ERα)positive breast cancer and then using long term anti-hormone adjuvant therapy(5-10 years)has reduced recurrences and ***,resistance continues to occur and improvements are required to build on the success of tamoxifen and aromatase inhibitors(AIs)established over the past 40 *** translational research has described the evolution of acquired resistance of breast cancer cell lines to long term estrogen deprivation that parallels clinical experience over ***,recent reports have identified mutations in the ERαobtained from the recurrences of AI treated *** mutations allow the ERαto activate without ligands and auto stimulate metastatic tumor ***,the new biology of estrogen-induced apoptosis in acquired resistant models in vitro and in vivo has been interrogated and applied to clinical *** and stress are emerging concepts occurring in the process of acquired resistance and estrogen-induced apoptosis with different *** this review,we will present progress in the understanding of acquired resistance,focus on stress and inflammatory responses in the development of acquired resistance,and consider approaches to create new treatments to improve the treatment of breast cancer with endocrine resistance.